Skip to main content
Premium Trial:

Request an Annual Quote

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The splicing subgroup of the ClinGen Sequence Variant Interpretation Working Group provides recommendations on how to evaluate splicing variant data in the American Journal of Human Genetics this week. Though the American College of Medical Genetics and Genomics and the Association for Molecular Pathology established a framework in 2015 for classifying variants, the authors of the new paper note that the application of these guidelines by variant curation expert panels has varied. In their paper, the working group offers a standardized guidance on how to apply evidence codes to splicing predictions, splicing assays, and other functional data. "We describe generic protocols useful for assigning strength levels to different evidence criteria to facilitate recalibration of code strengths as new information accrues," the subgroup writes. "We also provide a generic decision tree to guide variant assessment with combinations of evidence codes relating to variant location, splicing predictions, splicing assay data, and variant type."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.